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Hypogonadism, whether caused 
by the failure of gonadal develop-
ment or function, frequently results 
in bone loss. In a research article in 
the April 21, 2006 issue of Cell, Sun 
et al. investigated the role of follicle-
stimulating hormone (FSH) in the 
bone loss that is characteristic of 
hypogonadal mice. They report that 
female mice lacking either FSHβ or 
its receptor (FSHR) are resistant 
to bone loss despite hypogonad-
ism. Sun et al. conclude that FSH 
is directly responsible for bone loss 
in hypogonadal female mice with 
unimpaired FSH action (Sun et al., 
2006). We challenge the proposal 
that FSH is required for hypogo-
nadal bone loss. We suggest that 
the two mouse models used in the 
Sun et al. study have hormonal fea-
tures—raised levels of luteinizing 
hormone (LH) and testosterone as 
a secondary consequence of FSH 
loss—that could explain the pres-
ervation of bone, without any need 
to invoke additional bone-specific 
actions of FSH.
LH stimulates ovarian theca cells 
to produce testosterone (Kumar, 
2005). This effect is especially pro-
nounced in the absence of FSH sig-
naling when LH levels are increased 
due to overlapping negative feed-
back pathways in the hypothala-
mus and pituitary. The increased 
LH levels in turn boost testosterone 
production by theca cells. Previous 
work in mice lacking FSHR showed 
that blood testosterone levels are 
increased up to 10-fold in imma-
ture and mature female mice (Balla 
et al., 2003; Danilovich et al., 2000; 
Abel et al., 2003). Moreover, uterine 
hypertrophy and other defects in 
mice lacking either FSHR or FSHβ 
are likely due to increased testoster-
one that is of ovarian origin (Abel et 
al., 2003). We argue that changes 
in the production of these sex ster-oids and not the loss of FSH sign-
aling account for the observations 
by Sun et al. Unfortunately, Sun et 
al. did not report the concentration 
of serum LH or testosterone in their 
two mouse models.
We have shown that in the hpg 
hypogonadal mouse, marked bone 
loss is present in males (Sims et al., 
2005). Sun and colleagues reported 
similar findings in female hpg mice 
in another recent study (Rajen-
dren et al., 2006). The hpg mouse 
is a naturally occurring model of 
hypogonadism caused by a muta-
tion in the gene encoding gonado-
tropin-releasing hormone (GnRH) 
(Cattanach et al., 1977; Mason et 
al., 1986a). These mice have post-
natal deficiencies in FSH, LH, and 
gonadal sex steroid hormones. 
As a consequence, the reproduc-
tive system fails to mature, render-
ing hpg mice a valuable model of 
human idiopathic hypogonadotropic 
hypogonadism. The hpg mouse 
remains sensitive to testosterone or 
estradiol because hormone replace-
ment reverses the deficits in mature 
somatic tissues (Singh et al., 1995; 
Spaliviero et al., 2004). Importantly, 
the bone deficit in hpg mice is rec-
tified by restoration of testosterone 
in males, or estradiol in females 
(Rajendren et al., 2006; Sims et al., 
2005), regardless of whether FSH/
LH secretion is increased or not. 
These observations demonstrate 
that FSH is not necessary for the 
loss of bone in hypogonadal mice, 
nor does FSH prevent the restoration 
of bone during androgen or estrogen 
replacement.
The claim that FSH enhances 
bone loss implies that hypogona-
dotropic women, such as those with 
functional or structural pituitary 
insufficiency, would have less bone 
loss than hypergonadotropic women 
who are deficient in estrogen due Cell 127, Decemto, for example, natural or surgical 
menopause. Corroboration of this 
prediction is lacking and appears 
implausible. We propose that the in 
vivo observations reported by Sun 
and colleagues are not attributable 
to the action of circulating FSH but 
rather are a reflection of the well-
established but overlooked effects 
of LH-dependent secretion of testo-
sterone on bone metabolism.
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